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Background: Long noncoding RNAs (lncRNAs) have emerged recently as a new class of genes that regulate
cellular processes, such as cell growth and apoptosis. The SPRY4 intronic transcript 1 (SPRY4-IT1) is a 708-bp lncRNA
on chromosome 5 with a potential functional role in tumorigenesis. The clinical significance of SPRY4-IT1 and the
effect of SPRY4-IT1 on cancer progression are unclear.
Methods: Quantitative reverse transcriptase PCR (qRT-PCR) was performed to investigate the expression of
SPRY4-IT1 in 48 breast cancer tissues and four breast cancer cell lines. Gain and loss of function approaches were
used to investigate the biological role of SPRY4-IT1 in vitro. Microarray bioinformatics analysis was performed to
identify the putative targets of SPRY4-IT1, which were further verified by rescue experiments, and by western
blotting and qRT-PCR.
Results: SPRY4-IT1 expression was significantly upregulated in 48 breast cancer tumor tissues comparedwith
normal tissues. Additionally, increased SPRY4-IT1 expression was found to be associated with a larger tumor size
and an advanced pathological stage in breast cancer patients. The knockdown of SPRY4-IT1 significantly suppressed
proliferation and caused apoptosis of breast cancer cells in vitro. Furthermore, we discovered that ZNF703 was a
target of SPRY4-IT1 and was downregulated by SPRY4-IT1 knockdown. Moreover, we provide the first demonstration
that ZNF703 plays an oncogenic role in ER (−) breast carcinoma cells.
Conclusions: SPRY4-IT1 is a novel prognostic biomarker and a potential therapeutic candidate for breast cancer.
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Despite the improved prognosis of breast cancer patients
because of early diagnosis, radical surgery and the devel-
opment of adjuvant therapy, breast cancer remains the
most common type of cancer among women [1,2]. Trad-
itional prognostic markers, such as the estrogen receptor
(ER), progesterone receptor (PR), HER2/NEU, and p53
[3,4], are insufficient indicators of tumor aggressiveness
and do not adequately discriminate between different
biological and clinical outcomes [5]. Therefore, a better* Correspondence: kemingwang@njmu.edu.cn; shuyongqian@csco.org.cn
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unless otherwise stated.understanding of the genetic and molecular characteris-
tics of breast cancer is urgently needed for early diagno-
sis, choice of the appropriate treatment and an improved
prognosis for patients with breast cancer.
Recent studies have demonstrated that a class of non-
protein-coding RNAs (ncRNAs), which are known as
long non-coding RNAs (lncRNAs), participates in cell
fate determination and human disease pathogenesis
[6-9]. lncRNAs are RNA molecules longer than 200 nu-
cleotides that are not translated into proteins [10,11]. An
increasing body of evidence has suggested that lncRNAs
are key regulators in several biological processes and are
increasingly recognized as diagnostic or prognostic can-
cer biomarkers, including in breast cancer [10,12-14].
For example, GAS5, a well-known lncRNA, is markedlys is an Open Access article distributed under the terms of the Creative
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as a diagnostic cancer biomarker [9,15-17]. Another
characterized lncRNA, HOTAIR, is overexpressed in
breast cancer, interacts with Polycomb Repressive Com-
plex 2 (PRC2) and alters the regulation of genes [18],
resulting in aberrant histone H3K27 methylation and
gene expression and further promoting cancer invasive-
ness and metastasis [18]. Our previous studies have also
shown that patients with higher lncRNA Loc554202 ex-
pression present an advanced pathological breast cancer
stage [19].
lncRNA-SPRY4-IT1 (GenBank Accession ID AK024556)
is derived from an intron of the SPRY4 gene. Khaitan et al.
[20] observed that SPRY4-IT1 is highly expressed in mel-
anoma cells compared with melanocytes. The knockdown
of SPRY4-IT1 expression results in defects in cell growth,
decreased invasion, and increased rates of apoptosis in
melanoma cells [20]. A study conducted by Zou et al. [21]
showed that aberrant expression of lncRNA SPRY4-IT1
may contribute to the generation of abnormal HTR-8/
SVneo trophoblast cells. However, the expression profile
and biological role of SPRY4-IT1 as well as its mechanism
in breast cancer remain largely unknown. In this study, weFigure 1 Relative expression of SPRY4-IT1 in breast cancer tissues an
epithelial cells. (A) Relative expression of SPRY4-IT1 in breast cancer tissue
(n = 48). SPRY4-IT1 expression was examined by qPCR and normalized to G
with the expression levels inMCF-10A and other cells. The results are prese
(B and C) The data are presented as the relative expression levels in tumo
a higher pathological stage and a larger tumor size (shown as -ΔΔCT). (D)
tissues and ER(+) breast cancer tissues(shown as -ΔΔCT). (E) The relative SP
MDA-MB-435S and MCF-7) were compared with human breast epithelial ceassessed the effects of SPRY4-IT1 expression on breast
cancer cell phenotypes in vitro. Our results suggest that
increased SPRY4-IT1 expression may play a role in breast
cancer carcinogenesis.
Zinc finger 703 (ZNF703) has been identified as the
genetic driver of the amplification at 8p12 in luminal B
tumors [22-26]. A recent study demonstrated that en-
hanced ZNF703 expression represses E-cadherin expres-
sion and increases lung metastases in a mouse model of
breast cancer [27]. In this study, we found that ZNF703
is a downstream target gene of SPRY4-IT1 and demon-
strated that ZNF703 promotes ER(−) breast carcinoma
cell proliferation and suppresses apoptosis in vivo.
Results
Expression of SPRY4-IT1 in breast cancer tissues and
breast cancer cell lines
qRT-PCR analysis was used to examine the SPRY4-IT1
levels in 48 breast cancer tissues and 48 matched normal
breast tissues. SPRY4-IT1 expression was upregulated
(P < 0.05) in cancerous tissues compared with normal tis-
sues (Figure 1A). We then evaluated the correlation of
SPRY4-IT1 expression with clinicopathological parametersd cells compared with adjacent normal tissues and normal breast
s (T) (n = 48) compared with corresponding non-tumor tissues (N)
APDH expression and the levels in the cells of interest were compared
nted as the -ΔΔCT changes in tumor tissues relative to normal tissues.
r tissues. SPRY4-IT1 expression was significantly higher in patients with
SPRY4-IT1 expression was assessed by qRT-PCR in ER(−) breast cancer
RY4-IT1 expression levels in breast cancer cell lines (MD-MB-231,
lls (MCF-10A), as assessed by qRT-PCR. * P < 0.05 and **P < 0.01.
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cance. As presented in Figures 1B and 1C, both larger tu-
mors, which represent a higher tumor burden, and more
advanced tumors are associated with increased SPRY4-IT1
expression. Furthermore, we found ER(−)breast cancer tis-
sues exhibit increased SPRY4-IT1 expression than ER(+)
breast cancer tissues (p < 0.01; Figure 1D). These analyses
demonstrate that SPRY4-IT1 may be a potential prognostic
biomarker for breast cancer patients. We then examined
the expression of SPRY4-IT1 in three human breast
cancer cell lines, namely MD-MB-231, MDA-MB-435S
and MCF-7 cells, and in the normal breast epithelium cell
line MCF-10A. Significantly higher expression of SPRY4-
IT1 was found in MDA-MB-231 and MD-MB-435S cells,
compared with MCF-10A cells (p < 0.01; Figure 1E), but
MCF-7 cells expressed relatively lower levels of SPRY4-IT1
compared with MCF-10A cells (p <0.01; Figure 1E). These
results are consistent with our previous findings. There-
fore, SPRY4-IT1 was depleted in MD-MB-231 and MD-
MB-435S cells, which exhibit a higher expression of
SPRY4-IT1. In addition, SPRY4-IT1 was over-expressed in
the MCF-7 cell line after transfection of pcDNA3.1-
SPRY4-IT1, which generates a relatively lower level of
SPRY4-IT1 expression. The ectopic expression and knock-
down of SPRY4-IT1 in cells were confirmed by qRT-PCR
(p < 0.01; Additional file 1: Figure S1A and S1B).
SPRY4-IT1 promotes breast cancer cell proliferation
in vitro
To assess the biological role of SPRY4-IT1 in breast can-
cer, we observed its effect on cell proliferation. As shown
in Figure 2A, MDA-MB-231 and MDA-MB-435S cells,
which exhibit naturally high SPRY4-IT1 expression levels,
displayed a lower cell viability rate than control cells after
SPRY4-IT1 knockdown. Moreover, MCF-7 cells, which
exhibit naturally low SPRY4-IT1 expression, exhibited a
notably higher cell viability rate after overexpression of
SPRY4-IT1 than that observed in the controls infected
with the empty vector. Furthermore, cell proliferation was
also measured using a colony formation assay. Compared
with the control cells, SPRY4-IT1 knockdown in MDA-
MB-231 and MDA-MB-435S cells resulted in markedly
decreased colony formation abilities (p < 0.05; Figure 2B).
Similarly, SPRY4-IT1-overexpressing MCF-7 cells dis-
played significantly increased colony formation (p < 0.05;
Figure 2B). EdU (red)/Hoechst (blue) immunostaining
also confirmed this result (Figure 2C). These findings indi-
cate that SPRY4-IT1 may be closely associated with the
proliferation of breast cancer cell lines.
Downregulation of SPRY4-IT1 promotes G1 arrest and
causes apoptosis in breast cancer cells
To probe the potential mechanisms of SPRY4-IT1 in the
proliferation of breast cancer cells, we examined the cellcycle in MDA-MB-231 and MDA-MB-435S cells
through flow cytometry. After treatment with si-SPRY4-
IT1 or si-NC for 48 h, SPRY4-IT1 knockdown led to a
significant accumulation of cells at the G0/G1-phase
(p < 0.05) and a significant decrease in cells in the S-phase
(p < 0.05; Figure 3A). Consistently, cyclin D1 protein ex-
pression was also disrupted in the si-SPRY4-IT1-trans-
fected breast cancer cells compared with the control cells
(Figure 3B).
We then, investigated the effects of SPRY4-IT1 knock-
down on apoptosis. The percentages of apoptotic cells
were significantly increased in the treated group com-
pared with the control group (p < 0.05; Figure 3C). Con-
sistently, microscopic analysis of TUNEL staining in
MDA-MB-231 and MDA-MB-435S cells also showed
that the knockdown of SPRY40-IT1 resulted in a higher
number of apoptotic cells compared with the controls
(Figure 4D). Additionally, the western blot analysis show
that Bax protein was significantly increased in si-SPRY4-
IT1-treated cells, whereas the Bcl-2 protein level was de-
creased (Figure 4E). Taken together, the flow cytometric
analysis, TUNEL staining and protein analysis results
suggested that SPRY4-IT1 has exerts a critical effect on
breast cancer cell apoptosis.
Gene expression profiling
To analyze the transcriptional changes associated with
SPRY4-IT1 knockdown, we applied microarray analysis
to identify genes that exhibited a change in expression
after SPRY4-IT1 knockdown in MDA-MB-231 cells. The
profiling analyses identified 149 probe-set level transcripts
as being significantly differentially expressed (at least a
two-fold change in expression and a p-value ≤ 0.05) in
cells after SPRY4-IT1 knockdown compared with control
cells (Figure 4A, Additional file 2: Table S1). Of the dif-
ferentially expressed genes, 66 were upregulated by at least
2-fold, and 83 were downregulated by at least 2-fold.
Figure 4B summarizes the top ten upregulated or down-
regulated genes, organized by the average fold differences
(a complete list can be found in Additional file 2: Table S1).
To validate the microarray data, qRT-PCR was used
to analyze the same RNA samples subjected to trans-
criptome microarray analysis. Of the 14 differentially
expressed genes, ten were selected: the top five upregu-
lated genes (AMZ2, ZYX, NOL6, TCEB1, and IQSEC1)
and the top five downregulated genes (TMEM185B,
ZNF703, HSP90B3P, GSDMB, and SKA2). As shown in
Figure 4C and 4D, the trend (upregulation or downreg-
ulation) in the change expression of all ten selected
genes were consistent with the microarray analysis re-
sults, validating the accuracy of the microarray data.
Moreover, we found that ZNF703 exhibited the most
substantial change in gene expression in response to
SPRY4-IT1 knockdown (Figure 4C and 4D). To further
Figure 2 Effects of SPRY4-IT1 on breast cancer cell proliferation in vitro. (A) An MTT assay was performed to determine the proliferation of
MDA-MB-231, MDA-MB-435S and MCF-7 cells. The data are presented as the means ± S.D. from three independent experiments. (B) Colony-forming
growth assays were performed to determine the proliferation of MDA-MB-231, MDA-MB-435S and MCF-7 cells. The colonies were counted and
captured. (C) The proliferating MDA-MB-231, MDA-MB-435S and MCF-7 cells were labeled with EdU. The Click-it reaction revealed EdU staining (red).
The cell nuclei were stained with Hoechst 33342 (blue). The images are representative of the results obtained. *P < 0.05 and **P < 0.01.
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expression, we measured the ZNF703 levels in MDA-
MB-231 and MDA-MB-435S cells transfected with
SPRY4-IT1-siRNA and found decreased mRNA and
relative protein expression levels of ZNF703, whereas
MCF-7 cells transfected with pCDNA-SPRY4-IT1 ex-
hibited increased ZNF703 mRNA and relative pro-
tein expression levels compared with the controls
(Figure 4E, 4 F and 4G). Thus, ZNF703 may represent
an important downstream effector of SPRY4-IT1 that
potentially mediates the effects of this lncRNA on
tumor growth.ZNF703 expression is SPRY4-IT1-inducible in vitro and is
upregulated in primary breast cancer
ZNF703 has been identified as a novel oncogene in hu-
man breast cancer [22,24,25]. Recently, Reynisdottir
found that high ZNF703 expression, independent of
amplification, is correlated with poorer prognosis for
breast cancer patients with ER-positive luminal tumors,
particularly of the luminal B subtype [28]. However, it is
currently unclear whether ZNF703 has similar prognos-
tic power in ER(−) breast carcinoma.
To assess the contribution of ZNF703 to the biological
effects of ER(−) breast carcinoma, we evaluated the
Figure 3 Effect of SPRY4-IT1 on the cell cycle and apoptosis of breast cancer cells in vitro. MDA-MB-231 and MDA-MB-435S cells were
transfected with si-SPRY4-IT1 and si-NC, respectively. (A) The bar chart represents the percentage of cells in the G0/G1, S, or G2/M phase, as
indicated. The data are presented as the means ± SD from three independent experiments. *P < 0.05. (B) After SPRY4-IT1 knockdown in
MDA-MB-231 and MDA-MB-435S cells, the cyclinD1 protein level is diminished compared with the level observed in the control group, as determined
by western blot analysis. (C) The percentage of apoptotic cells was determined by flow cytometric analysis. The data represent the means ± SD from
three independent experiments. *P < 0.05. (D) Apoptosis in MDA-MB-231 and MDA-MB-435S cells after SPRY4-IT1 knockdown was detected through
TUNEL staining. (E) The Bax and Bcl-2 protein levels were elevated in MDA-MB-231 and MDA-MB-435S cells after SPRY4-IT1 expression was blocked
compared with the control group.
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proliferation and apoptosis in MDA-MB-231 and MDA-
MB-435S cells. First, we assessed ZNF703 expression in
three human breast cancer cell lines by qRT–PCR
(Figure 5A). All of the cell lines expressed notably higher
levels of ZNF703 compared with human breast epithelial
cells (MCF-10A), but MDA-MB-231 and MDA-MB-
435S cells (ER(−)) expressed relatively lower levels of
ZNF703 compared with MCF-7 cells (ER(+)).The function of ZNF703 in ER(−) breast carcinoma
cells was manipulated with small interfering RNAs
(siRNAs) in MDA-MB-231 and MDA-MB-435S cells.
Forty-eight hours after transfection, the ZNF703 mRNA
and relative protein levels were substantially down-
regulated compared with the levels observed in the
respective control cells (Additional file 3: Figure S2A
and S2B). Moreover, we used pCDNA-ZNF703 to up-
regulate the endogenous ZNF703 expression in MDA-
Figure 4 Gene expression profiling in MDA-MB-231 cells following SPRY4-IT1 knockdown. (A) Clusters of genes altered by SPRY4-IT1
knockdown. The heat map reveals clusters of genes. The green color indicates genes that are up regulated compared with the control cells, and the
red color indicates genes that down regulated compared with the control cells. The cells in which SPRY4-IT1 was knocked down are presented as A1
and C1, and the control cells are presented as A2, B2 and C2. (B) Top 10 genes significantly upregulated or down regulated in MDA-MB-231 cells
following SPRY4-IT1 knockdown. (C, D) The differential gene expression obtained from the microarray analyses was confirmed by qRT-PCR analysis of
10 selected genes using the gene specific primers shown in Additional file 2: Table S1. The data represent the means of triplicate experiments
normalized to the GAPDH level and are presented as the relative fold changes (RFC) of the levels in the MDA-MB-231 cells after SPRY4-IT1 knockdown
compared with the levels in the Scr-control cells. (E, F) qPCR analysis of the ZNF703 expression levels in MDA-MB-231 and MDA-MB-435S cells after
transfection with scrambled siRNA and si-SPRY4-IT1 (E) and in MCF-7 cells after treatment with an empty vector and pcDNA- SPRY4-IT1 (F). The data
are presented as the means ± SD from three independent experiments. **P < 0.01. (G) The ZNF703 protein level is elevated in MDA-MB-231 and
MDA-MB-435S cells after transfection with si-SPRY4-IT1 and in MCF-7 cells after transfection with pcDNA-SPRY4-IT1.
Shi et al. Molecular Cancer  (2015) 14:51 Page 6 of 13MB-231 cells, and the efficiency of the transfection into
MDA-MB-231 was 16-fold compared with that found for
the control cells (Additional file 3: Figure S2C and S2D).
We then examined the impact of ZNF703 knockdown in
the MDA-MB-231 and MDA-MB-435S cells lines. Com-
pared with the control group, transfection with si-ZNF703
resulted in a significant decrease in MDA-MB-231 andMDA-MB-435S cell viability, as monitored through an
MTT assay (Figure 5B and 5C). In addition, a long-term
survival assay showed that ZNF703 knockdown also
attenuated the colony-forming ability of the population
(Figures 5D and 5E). Additionally, EdU (red)/Hoechst
(blue) immunostaining also confirmed this comparison
(Figures 5F, 5G and 5H).
Figure 5 (See legend on next page.)
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Figure 5 Effects of SPRY4-IT1 on ER(−) breast cancer cell proliferation and apoptosis in vitro. (A) The relative ZNF703 expression level in
breast cancer cell lines (MDA-MB-231, MDA-MB-435S and MCF-7) compared with the level in human breast epithelial cells (MCF-10A) was assessed
by qRT-PCR. (B, C) An MTT assay was performed to determine the proliferation of MDA-MB-231 and MDA-MB-435S cells treated with scrambled
siRNA and si-ZNF703. The data are presented as the means ± S.D. from three independent experiments. (D, E) Colony-forming growth assays were
performed to determine the proliferation of MDA-MB-231 and MDA-MB-435S cells treated with scrambled siRNA and si-ZNF703. The colonies
were counted and captured. (F, G, H) Proliferating MDA-MB-231 and MDA-MB-435S cells treated with scrambled siRNA or si-ZNF703 were labeled
with EdU. The Click-it reaction revealed EdU staining (red). The cell nuclei were stained with Hoechst 33342 (blue). The images are representative
of the results obtained. (I, J) The percentage of apoptotic cells was determined by flow cytometric analysis. The data are presented as the
means ± SD from three independent experiments. (K) An MTT assay was performed to determine the proliferation of MDA-MB-231 cells treated
with empty vector and pcDNA-ZNF703. (L, M) Colony-forming growth assays were performed to determine the proliferation of MDA-MB-231 cells
treated with empty vector and pcDNA-ZNF703. The colonies were counted and captured. Three independent experiments were performed for
each assay. *P < 0.05 and **P < 0.01.
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down on apoptosis. As shown, the percentages of apop-
totic cells were significantly increased in the treated
group compared with the control group (p < 0.05;
Figure 5I and 5J).
To further test the effects of ZNF703, we examined the
impact of ZNF703 overexpression in the MDA-MB-231
cell line. An MTT assay was performed to monitor the ef-
fect of ZNF703 overexpression on cell growth and prolif-
eration at different times, and a colony forming assay was
also performed. The cell proliferation rate in the cultures
transfected with pCDNA-ZNF703 96 h after transfection
was barely distinguishable from that of the control cells
(Figure 5K). Additionally, the transfection of pCDNA-
ZNF703 also mildly protected the colony-forming ability
of the cells compared with the negative control (Figure 5L
and 5M). However, the number of apoptotic cells was not
significantly decreased in the treated group compared
with the control group (Additional file 4: Figure S3A and
S3B). Taken together, these results suggest that ZNF703
can promote the proliferation and suppress the apoptosis
of ER(−) breast cancer cells in vivo.
SPRY4-IT1 exerts its effect through ZNF703 for both
promotion of proliferation and inhibition of apoptosis
To investigate whether ZNF703is involved in the
SPRY4-IT1induced increase in breast cancer cell prolif-
eration, we performed rescue experiments. After trans-
fection with si-SPRY4-IT1, MDA-MB-231 cells were
cotransfected with pCDNA-ZNF703. We found that
ZNF703 overexpression partially compromised the effects
of SPRY4-IT1 on breast cancer proliferation (Figure 6A
and 6C), whereas the knockdown of ZNF703 had the
opposite effects (Figure 6B and 6D). Consistently, the
TUNEL staining results also showed that ZNF703 overex-
pression partially compromised the effects of knockdown
of SPRY40-IT1 on breast cancer apoptosis (Figure 6E),
whereas the knockdown of ZNF703 had the opposite ef-
fects (Figure 6F). Our results reveal that the effect of
SPRY4-IT1 on breast cancer is at least in part through tar-
geting ZNF703.Discussion
It is clear that mammalian genomes encode numerous
long noncoding RNAs [29-32]. Nonetheless, the func-
tional roles of most of these transcripts remain obscure
[33]. In particular, the involvement of lncRNAs in breast
cancer pathogenesis and progression is not widely
studied.
In our study, we first found that lncRNA SPRY4-IT1
was significantly upregulated in breast cancer tissues
compared with adjacent normal tissues. Our data indi-
cated that a high expression of this lncRNA is correlated
with a larger tumor size and a later stage of tumor deve-
lopment in breast cancer patients, indicating that
SPRY4-IT1 may be a promising prognostic biomarker
for breast cancer patients. Additionally, we found that
ER(−) breast cancer tissues present increased SPRY4-IT1
expression than ER(+) breast cancer tissues, which lead
us to hypothesize that SPRY4-IT1 may be negatively cor-
related with estradiol.
Because high SPRY4-IT1 expression is associated with
an aggressive tumor phenotype in breast cancer, we
speculated that SPRY4-IT1 may play a significant role in
tumor biology. First, we chose representative breast can-
cer cell lines and investigated SPRY4-IT1 expression in
these cell lines comparedwith a non-tumor breast cell
line. We found that the MDA-MB-231 and MDA-MB-
435S cell lines exhibited high SPRY4-IT1 expression,
whereas the MCF-7 cell line exhibited low SPRY4-IT1
expression compared with normal breast epithelial cells
(MCF-10A), which is in agreement with our findings in
breast cancer tissues. We then determined whether
SPRY4-IT1 expression influences tumor-like characteris-
tics such as proliferation and apoptosis. Indeed, the
knockdown of SPRY4-IT1 inhibites cell proliferation and
increases cell apoptosis in MDA-MB-231 and MDA-
MB-435S cell lines, whereas the ectopic expression of
SPRY4-IT1 significantly enhances cell proliferation in
MCF-7 cell lines. Moreover, we demonstrated that the
mechanism may be associated with G0/G1 cell cycle ar-
rest, which is in agreement with our clinical findings that
SPRY4-IT1 is significantly correlated with the tumor size
Figure 6 SPRY4-IT1 promotes breast cancer cell proliferation partly through the upregulation of ZNF703 expression. (A) An MTT assay
was performed to determine the proliferation of MDA-MB-231 cells transfected with scrambled siRNA, pCDNA-ZNF703,si-SPRY4-IT1 + pCDNA-
ZNF703 or si-SPRY4-IT1. (B) An MTT assay was performed to determine the proliferation of MDA-MB-231 cells transfected with scrambled siRNA,
si-ZNF703, si-SPRY4-IT1 + si-ZNF703 or si-SPRY4-IT1. The data are presented as the means ± S.D. from three independent experiments. *P < 0.05.
(C, D) Colony-forming growth assays were performed to determine the proliferation of MDA-MB-231 treated with scrambled siRNA, pCDNA-ZNF703,
si-SPRY4-IT1 + pCDNA-ZNF703, si-ZNF703, si-SPRY4-IT1 + si-ZNF703, or si-SPRY4-IT1. (E, F) Apoptosis in MDA-MB-231 cells treated with scrambled siRNA,
si-SPRY4-IT1 + pCDNA-ZNF703, si-SPRY4-IT1 + si-ZNF703, or si-SPRY4-IT1 was detected through TUNEL.
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may affect breast cancer progression by affecting cell
proliferation and apoptosis.
Although SPRY4-IT1 has been shown to play crucial
biological roles and is dysregulated in various human
cancers [20,21,34,35], the precise regulatory mechanisms
of SPRY4-IT1 expression remain largely unknown. A
previous study demonstrated that the Polycomb group
protein enhancer of zeste homolog 2 (EZH2) can regu-
late the transcript levels of SPRY4-IT [34]. However, thedownstream pathway is not currently known. To explore
the molecular mechanism through which SPRY4-IT con-
tributes to cell proliferation and causes apoptosis in
breast cancer cells, we investigated potential target genes
involved in cell proliferation and apoptosis through a
microarray analysis. We found that the ZNF703 exhibits
the most substantial expression change in response to
SPRY4-IT1 knockdown. Moreover, qRT-PCR analysis
demonstrated that the ZNF703 mRNA levels are reduced
or elevated after the knockdown or overexpression of
Shi et al. Molecular Cancer  (2015) 14:51 Page 10 of 13SPRY4-IT1, respectively. The western blot analysis also
confirmed that the ZNF703 protein levels are regulated by
SPRY4-IT1.
ZNF703, a gene that plays an oncogenic role in lu-
minal B type breast cancer [22-24], is likely the most
functionally important gene in the 8p12 amplicon
[22,24-26]. Its role in breast cancer progression or me-
tastasis was demonstrated in a mouse model of breast
cancer [27]. These functions suggest that ZNF703 plays
an important role in breast cancer formation and pro-
gression [28]. However, few studies have examined the
biological function of ZNF703 in ER (−) breast carcin-
oma. In this study, we provide the first demonstration
that ZNF703plays an oncogenic role in ER (−) breast
carcinoma cells and that the expression level of ZNF703 is
higher in MDA-MB-231 and MDA-MB-435S cells com-
pared with human breast epithelial cells (MCF-10A). The
knockdown of ZNF703 was found to inhibit cell prolifera-
tion and increase cell apoptosis in MDA-MB-231 and
MDA-MB-435S cell lines, whereas the ectopic expression
of ZNF703 significantly enhancs cell proliferation in
MCF-7 cell lines. Moreover, we demonstrate that the
mechanism may be associated with G0/G1 cell cycle
arrest. To further confirm that ZNF703 is involved in the
SPRY4-IT1-induced increase in breast cancer cell pro-
liferation, we performed rescue experiments. The results
showed that the cotransfection of si-SPRY4-IT1 and
pCDNA-ZNF703 partially rescued the proliferation in-
duced by SPRY4-IT1 upregulation and the apoptosis
induced by SPRY4-IT1 downregulation, indicating that
SPRY4-IT1 increases cell proliferation and inhibits cell
apoptosis partially through ZNF703. However, the precise
molecular mechanism regulating how SPRY4-IT1 controls
ZNF703 remains unclear and requires further investigation.
Conclusion
In summary, this study shows that the expression of the
lncRNA SPRY4-IT1 is increased in breast cancer tissues
and that increased expression of SPRY4-IT1 is sig-
nificantly associated with a larger tumor size and a later
stage of tumor development in breast cancer patients.
Moreover, the knockdown of SPRY4-IT1 has the effects
of suppressing breast cancer cell proliferation and causing
apoptosis. Further insights into the functional and clinical
implications of SPRY4-IT1 and its target ZNF703 may fa-
cilitate the identification of novel diagnostic or predictive
biomarkers and drug targets for breast cancer.
Materials and methods
Tissue collection
Paired breast cancer and adjacent normal breast tissue
were obtained from 48 patients who had undergone sur-
gical breast cancer resection between 2012 and 2013 at
Second Affiliated Hospital of Nanjing Medical, China.Local or systemic treatment had not been performed in
these patients prior to the operation, and the clinico-
pathological characteristics of the patients with breast
cancer are summarized in Additional file 5: Table S2.
Samples were immediately macrodissected at the time of
surgery and placed directly in RNALater stabilization so-
lution (Qiagen, Hilden, Germany). All of the tissues were
stored at −80°C until total RNA was extracted. The ER
status, pathological stage, grade and nodal status were
appraised by an experienced pathologist. Clinicopatho-
logical characteristics including tumor-node-metastasis
(TNM) staging were also scored. The non-tumorous tis-
sues were 5 cm from the edge of the tumor, contained
no obvious tumor cells and were also evaluated by the
pathologist. All of the experiments were approved by the
Research Ethics Committee of the Second Affiliated
Hospital of Nanjing Medical University and written in-
formed consent was obtained from all patients.
Cell lines and culture conditions
The human breast cancer cell lines MD-MB-231 MD-
MB-435S MCF-10A and MCF-7 were purchased from
the Institute of Biochemistry and Cell Biology of the
Chinese Academy of Sciences (Shanghai, China). MD-
MB-231 and MD-MB-435S were cultured in Leibovitz’s
L-15 Medium (L-15; Gibco) in humidified air at 37°C
with 100% air. MCF-10A and MCF-7 were cultured in
Dulbecco’s Modified Eagle’s Medium (DMEM; Invitro-
gen) in humidified air at 37°C with 5% CO2. All of the
media were supplemented with 10% fetal bovine serum
(10% FBS), 100U/ml penicillin, and 100 mg/ml strepto-
mycin (Invitrogen, Shanghai, China).
RNA extraction and qRT-PCR analyses
RNA extraction and qRT-PCR analyses were performed
as described previously [19]. The primer sequences are
shown in Additional file 6: Table S3.
Western blot assay and antibodies
Western blot analysis was performed as previously de-
scribed [19]. β-actin was used as a loading control, and
the mean ± SD was calculated from 3 individual experi-
ments. β-actin (1:1,000) antibody was used as a control
and purchased from Sigma-Aldrich (USA). Anti-cyclinD1,
anti-bcl-2, and anti-bax (1:1,000) antibodies were pur-
chased from Cell Signaling Technology, Inc. (CST). The
anti-ZNF703 (1:1,000) antibody was purchased from
Abcam (USA).
Small interfering RNA and plasmids DNA transfections
Small interfering RNA (siRNA) and nonspecific control
siRNA was synthesized (Carlsbad, California, USA) and
transfected using Lipofectamine 2000. The sequences of
the siRNAs are described in Additional file 6: Table S3.
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sized and subcloned into the pCDNA3.1 (Invitrogen,
Shanghai, China) vector. The pCDNA constructs or the
empty vector were transfected into breast cancer cells
cultured on six-well plates according to the manufac-
turer’s instructions. The empty vector was used as the
control. The expression level of SPRY4-IT1 and ZNF703
was detected by qRT-PCR.
Determination of cell viability and colony formation assay
Forty-eight hours after siRNA or DNA transfection,
3000 cells per well were seeded into 96-well plates. After
6, 24, 48, 72 and 96 h of culture, cell viability was mea-
sured using the Cell Proliferation Reagent Kit I (MTT;
Roche Applied Science) as described previously [19].
Clonogenic assays were performed as described pre-
viously [19]. The colony formation ratio was calculated
as “number of cells/initiative cell × 100 (%)”.
Cell apoptosis and cell cycle analysis
Cell apoptosis was analyzed 48 h after transfection by
Annexin V and propidium iodide (PI) staining as
described previously [19]. Cell cycle analysis was per-
formed 48 h after transfection with PI staining as de-
scribed previously [19]. Three independent experiments
were performed for each assay.
Ethynyl deoxyuridine (Edu) analysis
Proliferating cells were assessed using the 5-ethynyl-
2-deoxyuridine (EdU) labeling/detection kit (Ribobio,
Guangzhou, China) according to the manufacturer’s
protocol. Briefly, breast cancer cells were cultured in 96-
well plates at 5 × 103 cells per well and transfected with
plasmid DNA or siRNA for 48 h. Then, 50 μM EdU label-
ing medium was added to the cell culture and incubated
for 2 h at 37°C under 5% CO2. Next, the cultured cells
were fixed with 4% paraformaldehyde (pH 7.4) for 30 min
and treated with 0.5% Triton X-100 for 20 min at room
temperature. After washing with PBS, the samples were
stained with anti-EdU working solution at room
temperature for 30 min. Subsequently, the cells were incu-
bated with 100 μL Hoechst 33342 (5 μg/mL) at room
temperature for 30 min, followed by observation under a
fluorescent microscope. The percentage of EdU-positive
cells was calculated from five random fields in three wells.
TUNEL staining
Terminal deoxynucleotidyl transferase-mediated dUTP
nick end labeling (TUNEL) was performed with an
apoptosis detection kit (KeyGEN BioTECH, China) ac-
cordingly to the manufacturer’s instructions. Randomly
selected field without significant necrosis in 10 high-
power fields (6400) were assessed for TUNEL-positivecells. The index of TUNEL was calculated based on the
number of total nuclei and cells with green nuclei.
Microarray bioinformatics analysis
Total RNA, cRNA probe preparation, array hybridization
and data analysis were performed as described in the
Affymetrix manufacturer’s instructions. AffymetrixTM
HG-U133 Plus 2.0 whole genome chips were used (Santa
Clara, CA, USA). RNA log expression units were calcu-
lated from the Affymetrix GeneChip array data using the
GeneSpring GX (Agilent, Santa Clara, CA, USA). The de-
fault settings were used to background correct, normalize
and summarize all expression values. Significant differ-
ences between sample groups were identified using the
t-test based on a normalized value for each gene, and a
p-value was calculated using a modified permutation test.
Heatmap and principle component analysis (PCA) were
performed using GeneSpring GX software (Agilent, Santa
Clara, CA, USA) to provide a visual representation of how
the various sample groups are related. Gene annotation
and gene ontology were performed with Amigo. The
microarray data has been submitted to Gene Expression
Omnibus (GEO) database (GSE62507).
Statistical analysis
Statistical analysis was performed using SPSS software
(SPSS, Inc., Chicago, IL, USA). Clinicopathological data
were analyzed using the chi-square exact test. For compar-
ing the SPRY4-IT1 expression in breast cancer tissues and
matched normal breast tissues, paired t-test was used. For
comparisons between two samples, an unpaired two-tailed
t-test was performed. A p-value of <0.05 was considered
statistically significant. The results are reported as the
means ± SDs. Statistical significance was assigned at
P < 0.05 (*) or P < 0.01 (**). All experiments were per-
formed at least three times with triplicate samples.
Additional files
Additional file 1: Figure S1. qPCR analysis of the SPRY4-IT1expression
levels in MDA-MB-231 and MD-MB-435S cells after transfection with
scrambled siRNA and si- SPRY4-IT1 and in MCF-7 cells after treatment
with empty vector and pcDNA-SPRY4-IT1. All of the experiments were
performed in triplicate and the data are presented as the means ± SD.
*P < 0.05 and **P < 0.01.
Additional file 2: Table S1. The profiling analyses identified probe-set
level transcripts as being significantly differentially expressed in cells after
SPRY4-IT1 knockdown compared with control cells.
Additional file 3: Figure S2. qPCR and western blot analysis of the
ZNF703 expression levels in MDA-MB-231 and MD-MB-435S cells after
treatment with scrambled siRNA and si- ZNF703 and in MCF-7 cells after
treatment with empty vector and pcDNA-ZNF703. All of the experiments
were performed in triplicate and the data are presented as the means ± SD.
**P < 0.01.
Additional file 4: Figure S3. The percentage of apoptotic cells was
determined by flow cytometric analysis. The data are presented as the
means ± SD from three independent experiments.
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Patients.
Additional file 6: Table S3. Sequence of primers and siRNA.
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